| Secondary |
| Menopause |
27.7% |
| Interstitial Lung Disease |
11.5% |
| Post-traumatic Stress Disorder |
9.5% |
| Depression |
7.4% |
| Rheumatoid Arthritis |
7.4% |
| Breast Cancer |
6.1% |
| Menorrhagia |
5.4% |
| Drug Use For Unknown Indication |
3.4% |
| Relapsing-remitting Multiple Sclerosis |
3.4% |
| Contraception |
2.7% |
| Lung Adenocarcinoma |
2.7% |
| Product Used For Unknown Indication |
2.7% |
| Osteoporosis |
2.0% |
| Prostate Cancer Metastatic |
2.0% |
| Ankylosing Spondylitis |
1.4% |
| Migraine |
1.4% |
| Ovulation Induction |
1.4% |
| Blood Cholesterol Increased |
0.7% |
| Diabetes Mellitus |
0.7% |
| Diuretic Therapy |
0.7% |
|
| Renal Failure |
16.1% |
| Shock |
12.9% |
| Visual Impairment |
9.7% |
| Small Intestinal Haemorrhage |
6.5% |
| Weight Increased |
6.5% |
| Amnesia |
3.2% |
| Anaemia |
3.2% |
| Bone Density Decreased |
3.2% |
| Bone Loss |
3.2% |
| Breast Cancer |
3.2% |
| Breast Cancer Female |
3.2% |
| Cerebrovascular Accident |
3.2% |
| Dysuria |
3.2% |
| Emphysema |
3.2% |
| Endometrial Cancer |
3.2% |
| Explorative Laparotomy |
3.2% |
| Hysterectomy |
3.2% |
| Injection Site Bruising |
3.2% |
| Insomnia |
3.2% |
| Interstitial Lung Disease |
3.2% |
|
| Concomitant |
| Product Used For Unknown Indication |
13.7% |
| Metastases To Bone |
10.8% |
| Breast Cancer |
10.4% |
| Breast Cancer Metastatic |
6.7% |
| Osteoporosis |
6.6% |
| Prostate Cancer |
6.3% |
| Pain |
5.2% |
| Rheumatoid Arthritis |
4.7% |
| Depression |
4.1% |
| Back Pain |
4.0% |
| Hypertension |
3.9% |
| Drug Use For Unknown Indication |
3.7% |
| Hormone Replacement Therapy |
3.4% |
| Gastrooesophageal Reflux Disease |
2.8% |
| Breakthrough Pain |
2.5% |
| Hypercalcaemia |
2.5% |
| Prostate Cancer Metastatic |
2.4% |
| Asthma |
2.2% |
| Sleep Disorder |
2.1% |
| Menopause |
1.8% |
|
| Vomiting |
11.6% |
| Tooth Extraction |
11.0% |
| Wheezing |
11.0% |
| Wound Infection Staphylococcal |
7.6% |
| Pain In Jaw |
6.4% |
| Weight Decreased |
6.4% |
| Osteonecrosis |
5.2% |
| Pain |
5.2% |
| Nausea |
4.1% |
| Therapeutic Response Decreased |
4.1% |
| Off Label Use |
3.5% |
| Vision Blurred |
3.5% |
| Wound Debridement |
3.5% |
| Fatigue |
2.9% |
| Death |
2.3% |
| Dyspnoea |
2.3% |
| Metastases To Bone |
2.3% |
| Myalgia |
2.3% |
| Product Quality Issue |
2.3% |
| Prostate Cancer |
2.3% |
|
| Interacting |
| Attention Deficit/hyperactivity Disorder |
50.0% |
| Interstitial Lung Disease |
25.0% |
| Scleroderma |
25.0% |
|
| Hysterectomy |
50.0% |
| Thrombotic Thrombocytopenic Purpura |
50.0% |
|
